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ACHIEVING PROPER BALANCE IN RESEARCH WITH
DECISIONALLY-INCAPACITATED SUBJECTS: NAMI'S 1
PERSPECTIVES ON THE WORKING
GROUP'S PROPOSAL
LAURIE M. FLYNN*
RONALD S. HONBERG, J.D., M.ED.**
I. INTRODUCTION
Helen B., 32 years old, suffers from severe schizophrenia. Although she is
a bright, engaging individual, her brain disorder has had a profoundly nega-
tive impact on her life. She has been hospitalized on a number of occasions and
has experienced frequent periods of homelessness. The public mental health sys-
tem in her community has never provided her with the consistent treatment and
services she needs to maintain her stability. Often, she must wait for weeks to
get appointments at the local community mental health center, meaning that
she sometimes goes for long periods without any medication at all. As her symp-
toms worsen, she has difficulty maintaining her apartment or keeping appoint-
ments, usually leading to evictions and the termination of mental health
services because she is deemed "uncooperative."
Several years ago, through the help of a friend, Helen learned about a
research program involving the study of an experimental drug for the treatment
of schizophrenia. She was initially leery about entering a research program.
She had been involved in one before which she thought was a treatment protocol
but which turned out to be a study of the structure and biochemistry of the
brain. Nevertheless, she decided to seek entry into the study because she was
desperate to find treatment that could help her.
Before beginning the study, Helen met with the lead researcher and a so-
cial worker to discuss the study. They described the design of the study to her,
including the potential benefits of the experimental medication and the poten-
tial side effects. It was further explained to her that the study had been re-
viewed and approved by an institutional review board (IRB). She was given a
long, complicated informed consent document to read and sign. Although
Helen did not understand all of the information on the document, her desire to
1. National Alliance for the Mentally III ("NAMI") is a national, grassroots advocacy
organization comprised of 140,000 members who are persons with severe mental illnesses
and family members.
* Executive Director, NAMI
** Director of Legal Affairs, NAMI
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find a medication that worked for her was very strong, and she signed the
document.
During Phase I of the study, Helen was hospitalized so that the effects of
Haldol, the neuroleptic medication she was taking at the time she entered the
study, could be entirely "washed out" of her system. Since she was on no medi-
cation at all for about four weeks, her auditory hallucinations, delusions, and
other symptoms of her schizophrenia worsened. After four weeks, still on an
inpatient basis, she began a course of "new medication, " which turned out to be
placebo. During this period, her symptoms remained quite severe.
After four more weeks, she was placed on the experimental medication.
Fortunately, after a few days on this medication, her hallucinations and delu-
sions subsided significantly. This improvement continued for several weeks,
with few adverse side effects, at which time she was released into the commu-
nity. She continued to receive the medication for two years as an outpatient
following completion of the inpatient phase of the study. During this period,
she completed a training program, found a part-time job, and maintained an
independent apartment in the community.
Unfortunately, after two years, funding for the study terminated. Since
the Food and Drug Administration (FDA) had not yet approved the drug, it
was still considered to be experimental, and therefore, Medicaid would not pay
for it. Helen was right back where she had started, trying to find appropriate
treatment and a support system that would enable her to maintain her stability.
Severe mental illnesses such as schizophrenia, manic-depressive
illness, major depression and others, can be devastating for those who
suffer from them. These illnesses, now understood to be disorders -of
the brain, cause immense suffering and correlate significantly with
homelessness, joblessness, involvement with criminal justice systems,
and suicide.2 Historically, there were few effective treatments for dis-
eases like schizophrenia, and people who suffered from these brain
disorders were usually relegated to the back wards of public institu-
tions, out of the public sight, and therefore out of mind.' However,
recent breakthroughs in understanding the etiology, nature, and
treatments of these disor'ders offer renewed hope that people with
these disorders will be able to live meaningful, productive lives in
their communities.
2. See generally, E.F. ToRRE' ET AL., NATIONAL ALLIANCE FOR THE MENTALLY ILL AND
PUaLC CITIZENS HEALTH RESEARCH GROUP, CRIMINALUZING THE MENTALLY ILL: THE ABUSE OF
JAILS AS MENTAL HOSPITALS (1992); FEDERAL TASK FORCE ON HOMELESSNESS AND SEVERE
MENTAL ILLNESS, OUTCASTS ON MAIN STREET (1992); NATIONAL INSTITUTE ON DISABILITY
AND REHABILITATION RESEARCH, STRATEGIES TO SECURE AND MAINTAIN EMPLOYMENT FOR PEO-
PLE wrrIH LONG-TERM MENTAL ILLNESS (VoL. 1, 1992); A.WRoBLEK1, SUICIDE: WHY? (1995).
3. See generally GERALD N. GROB, THE MAD AMONG US (1994).
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These breakthroughs have occurred through biomedical re-
search. Although we do not yet understand exactly what causes schiz-
ophrenia and other brain disorders, new treatments have been
developed which control or even alleviate the most devastating symp-
toms of these disorders for many people.4 These remarkable advances
would not have occurred without the participation of individuals suf-
fering from severe mental illnesses as human subjects in research.
These individuals are truly heroes in the struggle to better under-
stand, treat, and eventually even eradicate these devastating brain
disorders.
Nevertheless, there are often considerable risks associated with
the participation of individuals as human subjects in research on se-
vere mental illnesses.5 Individuals participating in research protocols
that evaluate the efficacy and safety of potential new medications for
severe mental illnesses may not directly benefit from their participa-
tion in such research, and infrequently may experience negative con-
sequences from such participation.6 Moreover, brain disorders such
as schizophrenia are often characterized by fluctuations in the mental
or cognitive capacities of those who suffer from them.7 This means
that some individuals with these disorders, who participate as human
4. For example, "a typical anti-psychotic medication such as clozapine (Clozaril), ris-
peridone (Risperdal), and olanzapine (Zyprexia) have achieved promising results in suc-
cessfully alleviating the most florid symptoms of schizophrenia. See e.g., NAnONAL
ALLIANCE FOR THE MENTALLY ILL, UNDERSTANDING SCHIZOPHRENIA: WHAT You NEED TO
KNow ABOUT THIS MEDICAL ILLNESS at 6 (1996) (hereinafter NAMI]. Similarly, lithium
successfully controls the most debilitating symptoms of manic-depressive illness in approxi-
mately 80% of all recipients, and fluoxetine (Prozac), sertraline (Zoloft) and paroxetine
(Paxil) are quite effective in treating major depression. See, e.g., NATIONAL ALLIANCE FOR
THE MENTALLY ILL, UNDERSTANDING MAJOR DEPRESSION: WHAT You NEED To KNow ABOUT
THIS MEDICAL ILLNESS at 10 (1996); F.K. GOODWIN AND K.R. JAMISON, MANIC-DEPRESSIVE
ILLNESS (1990).
5. While we limit our discussion in this article to research on severe mental illnesses,
the points made conceivably could apply to research involving human subjects who suffer
from Alzheimer's disease, autism, Huntington's disease and other brain disorders which
can impact on the capacity of these individuals to understand the nature of the research or
make informed decisions about their participation in research.
6. For example, although biomedical research facilitated the discovery and approval
of clozaril as a breakthrough medication for the treatment of schizophrenia, a small
number of people who participated in research protocols studying clozaril developed
agranulocytosis. See e.g., J. Kane et al., Clozapine for the Treatment-Resistent Schizophrenic: A
Double-Blind Comparison with Chlorpromazine, 45 ARCHrVEs GEN. PSYCHIATRY 789 (Sept. 1988).
Agranulocytosis is a potentially deadly side effecit of clozaril characterized by a sudden
decrease in white blood cells resulting in rapid death if the drug is not immediately with-
drawn. See id. at 790. This side effect, and the importance of regularly monitoring the
white blood cell counts of clozaril patients, was discovered only after the deaths of several
individuals participating as human subjects in clozaril studies. See id.
7. See id at 789-90.
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subjects in biomedical research, may not always be capable of under-
standing the nature of specific research protocols or the potential
benefits and risks associated with these protocols.8
Helen's story illustrates both the potentially dramatic benefits of
research participation for people with severe mental illnesses and the
extreme vulnerability of those who participate as human subjects in
such research. Her experiences give rise to a number of complex eth-
ical questions. Examples follow:
* Should people with impaired capacity to provide informed con-
sent be allowed to participate in research as human subjects? If
yes, what types of research?
* Should research protocols using persons with brain disorders as
human subjects include formalized procedures for evaluating the
capacity of these subjects? If yes, who should be responsible for
conducting these assessments?
* What can be done to ensure that informed consent is elicited from
research participants (or their legally authorized representatives)
in a manner which best ensures that they understand the nature,
potential risks, and benefits of the research?
* What responsibility do IRBs have to ensure that procedures are
developed and implemented for protecting the well being of re-
search subjects whose capacity for informed decision making may
be impaired?
* What is the dividing line between research and clinical treatment
for people who enter into protocols involving the study of experi-
mental medications?
* Is it ethical to administer placebo to research subjects who agree to
participate in research with the expectation that they will have
access to experimental treatments?
* What obligations exist, if any, after funding for research is termi-
nated, to continue people on experimental medications that help
them?
According to the National Institute of Mental Health (NIMH), it
funds more than seventy-five percent of all biomedical research on
severe mental illness.9 All federally funded research on severe mental
illnesses is subject to federal regulations governing protections of
human subjects in research.' ° However, these regulations (hereinaf-
ter referenced as "the Common Rule") do not adequately address
most of the issues raised above. These rules provide general guide-
8. See NAMI, UNDERSTANDING SCHIZOPH'IRENIA, supra note 4, at 2-4.
9. See id.
10. 45 C.F.R. §§ 46.101-.404 (1996).
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lines for obtaining informed consent from research participants."
The federal regulations also assign significant responsibilities to IRBs
to evaluate and monitor research proposals to ensure that they com-
port with the requirements set forth in the rules.1 2  However,
although the regulations identify "persons with mental disabilities" as
a vulnerable population, they do not set forth specific guidelines or
requirements for protecting the rights and welfare of research partici-
pants with these disorders.13 Hence, research investigators and local
IRBs have generally assumed these responsibilities on an ad hoc basis.
Recently, concerns have arisen that not all IRBs effectively moni-
tor the well-being of vulnerable research subjects with brain disor-
ders.14 Particular attention has been focused on a case involving a
research protocol on severe mental illness at the UCLA Neuropsychia-
tric Research Institute of the University of California, Los Angeles
(UCLA). 5 In this case, a former research subject at the Neurop-
sychiatric Institute and his family alleged that researchers failed to
properly inform research subjects and their families about potential
risks associated with the particular protocol. 6 One aspect of this pro-
tocol involved withdrawing individuals from psychotropic medications
to study the relationship between drug withdrawal and psychiatric re-
lapse. The former research subject and his family claimed that they
were never informed of the true purpose of the protocol, or the risks
associated with withdrawal from medication."7 Because of this, they
alleged, he experienced homelessness, long-term psychiatric deterio-
ration, and extreme suffering. It was also alleged that at least one
11. See id.
12. See id.
13. The guidelines contained in the Common Rule were very much influenced by a
1978 report issued by the National Commission for the Protection of Human Subjects of
Biomedical and Behavioral Research. THE NATIONAL COMMISSION FOR THE PROTECTnON OF
HUMAN SUBJEcrs IN BIOMEDICAL AND BEHAVIoRAL RESEARCH, NATIONAL INSTIrTTEs OF
HEALTH, THE BELMONT REPORT (GPO 887-809, 1979). The Belmont Report identified four
distinct groups of vulnerable populations. These populations were (1) pregnant women
and fetuses; (2)-children; (3) prisoners; and (4) persons with mental disabilities. Id. How-
ever, while the Common Rule contains special protections for the first three populations, it
is virtually silent concerning special protections for individuals whose decisionmaking ca-
pabilities may, due to mental or cognitive disorders, be impaired. See id.; see also, Adil E.
Shamoo, Our Responsibilities Toward Persons with Mental Illness as Human Subjects in Research, 5
J. CAL. ALLANCE MENTALLY ILL 14 (1994).
14. SeeJ. Horowitz, For the Sake of Science: When Tony Lamadrid, a Schizophrenic Patient and
Research Subject at UCLA, Committed Suicide, It Set Off a National Debate: What Is Acceptable in
Human Experimentation and Who Decides?, L.A. TIMEs MAc., Sept. 11, 1994, at 16.
15. See id.
16. See id.
17. See id
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participant in the protocol committed suicide after similarly being
withdrawn from psychotropic medication."8
After an investigation, the Office for Protection From Research
Risks (OPRR) issued a report which concluded that the IRB-approved
informed consent documents for UCLA's Schizophrenic Disorders re-
search failed to comply with informed consent requirements set forth
in the regulations of the Department of Health and Human Services
(HHS). 9 Moreover, OPRR found that UCLA's IRB had been defi-
cient in monitoring informed consent documents and procedures.2 °
We do not believe that the problems raised in the UCLA case are
typical of all (or even many) research protocols for severe mental ill-
nesses. The experiences of members of NAMI strongly suggest that
most research on severe mental illnesses be conducted ethically, with
procedures in place to monitor the well being of vulnerable subjects.
However, the UCLA case raises several important questions. First, can
steps be taken to better ensure that research subjects and their in-
volved families adequately understand the nature, purposes, and pro-
cedures involved in research protocols? Second, are there limits on
the types of research which should be conducted on individuals who
may lack capacity to provide informed consent?
The Maryland Attorney General's working group was formed spe-
cifically to address questions 'like these.21 The group's mission is to
develop recommendations that strike an appropriate balance between
the need to proceed with vitally important biomedical research and
the equally important need to develop adequate protections for vul-
nerable individuals with brain disorders who participate as human
subjects in this research. In the remainder of this article, we will focus
on certain aspects of the group's draft recommendations, with partic-
ular emphasis on issues of concern to consumers and families.
II. SHOULD RESEARCH BE CONDUCTED ON DECISIONALLY-
INCAPACITATED SUBJECTS AT ALL?
Helen's case may be a typical illustration of the dilemma facing
researchers trying to communicate information about specific re-
18. See id.
19. Office for Protection From Research Risks Division of Human Subject Protections
(OPRR), Evaluation of Human Subject Research Protections in Schizophrenia Research
Conducted by the University of California Los Angeles 16-17 (May 11, 1994).
20. See id.'at 21.
21. The authors of this article wish to express their appreciation of the efforts of Jack
Schwartz, Chief Counsel, Opinions and Advice, whose leadership has been the driving
force in facilitating the development of the working group's proposal.
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search protocols to research participants with brain disorders. Argua-
bly, Helen was capable of providing informed consent at the
beginning of the protocol. As the protocol progressed and her psychi-
atric symptoms worsened, serious questions arose about whether she
remained capable of providing informed consent.
In some cases, it may be far clearer in the beginning of research
that specific research subjects may lack capacity to understand the
fundamental nature of the research or to provide informed consent to
participate in the research. The question then arises as to whether it
is ever appropriate to use incapacitated research subjects.
Under the Nuremberg Code, 2 developed in 1947, the answer was
clearly no.2" The Code established that the "voluntary consent of the
human subject is absolutely essential. This means that the person in-
volved should have legal capacity to give consent."2" Under this ap-
proach, research on decisionally-incapacitated subjects would not be
permissible under any circumstances.
The Nuremberg Code was written as a reaction to revelations of
cruel and sadistic experiments conducted by Nazi scientists on sub-
jects with mental retardation and other mental disabilities under the
rubric of "medical research."25 However, with the passage of time,
there was increased concern that the strict prohibitions contained in
the Nuremberg Code may have been unduly restrictive of legitimate
and humane research.26 Over time, the necessity of more specific
guidelines to govern biomedical research became increasingly
apparent.
27
Subsequent declarations or rules for protecting human subjects
participating in research have not contained the strict prohibitions
contained in the Nuremberg Code. For example, the Helsinki Code
of 196428 allowed for proxy consent or even a complete waiver of con-
22. The Nuremberg Code (1947), reprinted inJessica W. Berg, Legal and Ethical Complexi-
ties of Consent with Cognitively Impaired Research Subjects, 24 J. L. MED. & ETHICS 18, 18-19
(1996).
23. Id.
24. Id.
25. See Irene Stith-Coleman, CRS Report for Congress: Protection of Human Subjects
in Research at 2 (Feb. 28, 1994) (unpublished Congressional Research Service report to
Congress).
26. See id,
27. See id. at 4.
28. WORLD MEDICAL ASSOCIATION, DECLARATION OF HELSINKI: RECOMMENDATIONS Gum-
ING MEDICAL DOCTORS IN BIOMEDICAL RESEARCH INVOLVING HUMAN SUBJECTS (1964) re-
printed in GEORGE J. ANNAS & MICHEAL A. GRODIN, THE NAZI DOCTORS & THE NUREMBERG
CODE 331-33 (1992).
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sent if in the subject's best interests.29 The Helsinki Code established
a distinction between "therapeutic" and "non-therapeutic" research."0
While requiring informed consent " in situations where [a patient's]
illness results in cognitive impairments.""s
The federal Common Rule requires that informed consent be ob-
tained from all research subjects, or their legally authorized represent-
atives, regardless of whether the research is classified as therapeutic or
non-therapeutic.3 2 However, as stated earlier in this article, the Com-
mon Rule does not set forth specific guidelines for obtaining in-
formed consent and protecting the rights and. well-being of research
subjects with mental illnesses or other brain disorders.
Many people with severe mental illnesses participate in research
protocols in hopes of finding treatments that work for them. Stan-
dard treatments for brain disorders such as schizophrenia, manic-de-
pressive illness, and major depression do not work for some people.
In other cases, standard medications may alleviate the most devastat-
ing symptoms of the disorders but may also produce unpleasant or
even harmful side effects. As in Helen's example, entry into a re-
search protocol may represent a desperate effort to find a treatment
that alleviates the extreme suffering characteristic of these disorders.
The existence of a hard and fast rule prohibiting research using
decisionally-incapacitated individuals as subjects would have the effect
of barring those who are most severely ill from participating in re-
search which may alleviate their suffering and provide them with sig-
nificant benefits. This, in our opinion, would be unjust and
unnecessary. At the same time, the lack of specific rules establishing
guidelines for when and how research may be conducted on decision-
ally-incapacitated individuals creates the potential for problems like
those that occurred in the UCLA case. An ad hoc approach to evalu-
ating research protocols involving the participation of decisionally-in-
capacitated individuals does not, we believe, serve the best interests of
consumers or of the research community.
The working group's recommendations ss represent, in our view,
a judicious approach to determining when research using decision-
ally-incapacitated individuals as subjects is appropriate. The working
29. Id.; see also Berg, supra note 22, at 19.
30. See Berg, supra note 22.
31. Id.
32. 45 C.F.R.§ 46.116 (1996).
33. Jack Schwartz, Office of the Md Att'y' Gen., Third Report of the Maryland Attorney
General Working Group (August, 1997) (the Third Report is reprinted in Appendix B to
this issue of the Journal of Health Care Law & Policy) (hereinafter Third Report].
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group's proposal would allow for the participation of decisionally-in-
capacitated individuals in certain types of research, with safeguards in
place to protect these individuals from a violation of their civil rights
or from harm.
The proposal attempts to retain as much autonomy as possible in
research subjects, while at the same time allowing research to proceed
under certain circumstances when individuals lack the capacity to pro-
vide informed consent. The proposal seeks to achieve this balance by
(a) relying significantly, but riot exclusively, for substitute decision-
making on individuals specified as "research agents" or "health care
agents" in advance directives developed by decisionally-incapacitated
individuals (presumably, during periods of capacity) ,3 and (b) rely-
ing heavily (in most, but not all cases) on direct evidence of the wishes
of decisionally-incapacitated individuals pursuant to advance direc-
tives of other written or verbal representations.
"Research agents" and "health care" agents respectively have the
greatest authority for substitute decision-making under the working
group's proposal, because they have been specifically designated by
the decisionally-incapacitated individual to make decisions regarding
participation on his/her behalf.36 "Surrogates" and "proxy decision-
makers" respectively have less authority because they are not similarly
appointed by the individual, and may not, in fact, even be known to
the individual.3 7
34. See id.
35. See id.
36. Id. at A-6 (§ 20-502(t) of the draft legislation; (defining research agents as individu-
als who are designated by decisionally-incapacitated individuals to make research decisions
on their behalf). "Health care agents" are similarly designated to make health care deci-
sions, pursuant to the Maryland Health Care Decisions Act. MD. CODE ANN. HEALTH-GN. I
§ 5-601 (c) (1994) (defining a health care "Agent" as "an adult appointed by the declarant
under an advance directive made in accordance with the provisions of this subtitle to make
health care decisions for the declarant"). A declarant is further defined in this section in
subtitle 6(g) as "a competent individual who makes an advance directive while capable of
making and communicating an informed decision." Id. at § 5-601(g).
37. Third Report, supra note 33, at A-6 (§ 20-502(u) of the draft legislation; (defining
surrogate as "a disinterested adult who is neither a research agent nor a health care agent
but who is authorized by the Health Care Decisions Act to make health care decisions for
an individual, under the conditions specified in Section 5-605 of this article"). Of course,
as discussed elsewhere in this article, the provision of health care treatment is not the same
as research. See supra note 6. It could, therefore, be argued that surrogates should have no
authority to make decisions pertaining to research. "Proxy decision maker" is defined in
the working group's proposal as:
A disinterested adult who is not a health care agent, research agent, or surrogate
for a decisionally incapacitated individual and who is designated by an IRB to
consider whether to give informed consent, pursuant to sections 20-513(e) .and
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It should be noted that the working group's proposal also seeks
to protect decisionally-incapacitated research subjects by sharply limit-
ing the circumstances in which someone other than the individual
him/herself may consent to participate to research which is consid-
ered to be non-therapeutic. In such instances, the higher the poten-
tial risks of the research, the more limited the circumstances in which
substitute consent may be provided. For example, only research
agents may provide informed consent for participation in research
which is "more than a minor increment over minimal risk, with no
direct medical benefit", and then only if "the research is unambigu-
ously included in the individual's advance directive authorizing re-
search participation." 8
We have two concerns about this aspect of the working group's
proposal. First, the heavy reliance on advance directives (both for
designating "agents" and for evidence of the individual's specific
wishes regarding research) could have the effect of excluding from
potentially beneficial research those decisionally-incapacitated indi-
viduals who do not have the wherewithal or sophistication to develop
these documents. For example, Helen (in the above example) might
be excluded from participation (or ongoing participation) in the pro-
tocol if she does not know how to go about executing an advance
directive. To prevent this anomalous situation from occurring, the
group may wish to consider accepting alternative ways in which the
individual wishes of decisionally-incapacitated individuals can be doc-
umented, for example, evidence from family members.
Second, we are concerned that the working group's formulation
of those who are authorized to act on behalf of decisionally-incapaci-
tated individuals is lacking one important element. Families are fre-
quently in the best position to understand the wishes of their
decisionally-incapacitated family member and to therefore act on
their behalf. However, families are notably absent from those who are
authorized to provide substitute consent in the proposal. Since ad-
vance directives are in their infancy and are not yet being widely uti-
lized by people with severe mental illnesses and other brain disorders,
the absence of family members from the decision-making hierarchy
20-514(e), for a decisionally incapacitated individual who had executed an ad-
vance directive authorizing research participation.
Third Report, supra note 33, at A-5 (§ 20-502(q) of the draft legislation). These individuals
are authorized to act on behalf of decisionally-incapacitated individuals only for "direct
medical benefit" research or research which is classified by the IRB as "minimal risk, no
direct medical benefit." IM at A-5 (§ 20-502(q) of the draft legislation).
38. Id. at A-22 (§ 20-516(b) (1) (i) of the draft legislation).
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means that individuals who may not really know the decisionally-inca-
pacitated person may frequently be called upon to act on behalf of
those individuals.3 9
III. SUBJECT ASSENT
Recently, the Appellate Division of the New York State Supreme
Court struck down New York Office of Mental Health regulations gov-
erning psychiatric research involving "more than minimum risk" pa-
tients in state run facilities who are incapable of providing informed
consent. In TD. v. New York State Office of Mental Health4° the court
raised the issue of the surrogate consent procedures set forth in the
regulations.4 *
One aspect of these procedures which the court found particu-
larly troublesome was that there were no express provisions in the
New York State regulations requiring that patients be informed that
they had been found decisionally-incapacitated or that surrogate con-
sent procedures were being exercised.42 In fact, the court noted that
it was possible under the regulations to commence research on the
patient without ever informing the individual that he/she was partici-
pating in research.4" As indicated in the language of the case, the
working group acknowledges,
In that event, neither the determination of lack of capacity
itself nor the decisions of the surrogate are reviewable at the
patient's request. Indeed, given the lack of a notice require-
39. However, it should be noted that family members could conceivably be specified as
research agents" or "health care agents" by the decisionally-incapacitated individual. See
id. at A-6 (§ 20-502(t) of the draft legislation). Family members could also be appointed as
legal guardians. See id. at A-15 to A-16 (§ 20-512 of the draft legislation). The working
group's proposal specifies that guardians must be consulted prior to enrollment of individ-
uals in any kind of research. See id.
40. See T.D. v. New York State Office of Mental Health, 650 N.Y.S. 2d 173 (N.Y. App.
Div. 1996), appeal dismissed by 680 N.E.2d 617 (N.Y. 1997), leave to appeal granted by 684
N.E.2d 281 (N.Y. 1997), and appeal dismissed by 1997 WL 785461 (N.Y. Dec. 22, 1997).
41. Id. at 190. Under these regulations, once an individual was determined to lack ca-
pacity to consent to research, surrogate consent could be obtained from "an individual
appointed pursuant to a duly executed durable power of attorney; .. .or an individual
designated by the patient to consent or withhold consent to the patient's participation."
Id. at 188 (quoting N.Y. Comp. Codes R. & Regs. tit. 14 § 527.10(e) (2) (iii) (1996)). If the
patient designated no person, surrogate consent could be obtained from the patient's
spouse, parent, adult child, adult sibling, guardian, or a committee of the person author-
ized to consent to research. Id. at 188 (citing N.Y. Comp. Codes R. & Regs. tit. 14
§ 527.10(e)(2)[iv] (1996)). If none of these options were available, surrogate consent
could be obtained from "a close friend" of the patient or a court of competentjurisdiction.
Id.
42. See T.D., 650 N.Y.S.2d at 187.
43. See id
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ment, the patient may not even be informed of either deter-
mination and may not even be aware he or she is involved in
research .
The working group's proposal contains two important require-
ments, which, if adopted, will hopefully prevent the concerns articu-
lated by the T.D. court from occurring in Maryland. First, it requires
investigators to tell decisionally-incapacitated individuals, prior to
commencing the research, that they are being asked to participate in
research.4" It also requires researchers to provide these individuals
with the name of the legally-authorized representative who has con-
sented to their participation in the research. 6
Second, it requires investigators to obtain the assent of "any deci-
sionally-incapacitated individual who is capable of giving assent prior
to commencing the research." 47 Finally, the proposal emphasizes that
investigators may not involve individuals in research or actions related
to research if the individual expresses disagreement or refuses to
participate.48
IV. THE ASSESSMENT OF CAPACITY
Since the Common Rule does not address the issue of decisional
incapacity, it also does not provide guidelines to researchers about
procedures to follow in assessing the capacity of research subjects.
The working group's proposal similarly does not address this issue.4
While we have not seen specific data on the subject, it is entirely
possible that, in some instances, responsibility for determining the ca-
pacity of individual research participants with severe mental illnesses
or other brain disorders may fall on principal investigators themselves,
or on others directly involved in the research.
In view of potential conflicts of interest, it is not advisable for
those directly involved in research to assume the responsibility of mak-
44. See id., at 190.
45. See Third Report, supra note 33 at A-15 (§ 20-511 (a) (i) of the draft legislation).
46. See id. (§ 20-511 (a) (ii) of the draft legislation).
47. Id. at A-15 (§ 20-511 (b) of the draft legislation). The concept of assent has evolved
from the field of research on Alzheimer's disease. See generally RUTH DuKoFF & TREY SUN-
DERLAND, DURABLE POWER OF ATroRNEY AND INFORMED CONSENT WITH ALZHEIMER'S DISEASE
PATIENTS: A CLINICAL STUDY (1996). Assent is described as a combination of verbal agree-
ment and non-verbal behavior. See generally id
48. Third Report, supra note 33, at A-15 (§ 20-511(c) (i), (ii) of the draft legislation).
49. The working group is aware of the lack of specific guidelines for conducting capac-
ity assessments and may take up this issue at some point in the future.
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ing capacity determinations.5" Rather, we believe that someone not
directly involved in the research should make capacity determina-
tions. This, we believe, will better ensure that such determinations are
made objectively by outside experts who do not have direct interests
in the course or outcomes of the research protocols.
5
'
V. THE IMPORTANT ROLE OF IRBs
Even more so than under the Common Rule, the working
group's proposal would vest significant responsibilities in local IRBs
for evaluating, monitoring and overseeing research protocols involv-
ing the participation of decisionally-incapacitated individuals.52 In
the working group's proposal, the responsibilities of IRBs include the
following:
determining if a particular protocol involving the partici-
pation or potential participation of decisionally-incapaci-
tated individuals presents a reasonable prospect of direct
medical benefit to the group of subjects as a whole, 53
50. We believe that most researchers are highly scrupulous and concerned about the
well being of research subjects. However, there may, in some instances, be incentives for
researchers not to be vigilant in monitoring the capacity of vulnerable research partici-
pants or in failing to determine that certain individuals lack capacity, if such determina-
tions will delay or interfere with the course of the research protocol. On the opposite side
of the spectrum, the Court, in T.D., expressed concerns that the regulations in that state
governing research on institutionalized patients in New York State facilities may create
incentives for potential subjects to be found lacking in decisional capacity. T.D. v. New
York State Office of Mental Health 650 N.Y.S. 2d 173 (N.Y. App. Div. 1996), appeal dismissed
ly 680 N.E.2d 617 (N.Y. 1997), leave to appeal granted by 684 N.E.2d 281 (N.Y. 1997), and
appeal dismissed by 1997 WL 785461 (N.Y. Dec. 22, 1997). "Once a patient is deemed inca-
pable, his or her ability to have an objection or continued participation honored is se-
verely. . . curtailed by provisions allowing for override of the objection." Id. at 187.
51. In 1995, the NAMI Board of Directors adopted comprehensive policy concerning
protections for individuals who participate as human subjects in research. One section of
this policy addresses capacity determinations.
Research participants should be carefully evaluated before and throughout the
research for their capacity to comprehend information and their capacity to con-
sent to continued participation in the research. The determination of compe-
tence shall be made by someone other than the principal investigator or others
involved in the research.
National Alliance for the Mentally Il, Standards for Protecting the Well-Being of Individuals
Participating in Research, NAMI PUBLIC PoLIcY PLATORaM, (2d ed.. 1997) (a copy of these
standards is reprinted in the Appendix to this article).
52. See Third Report, supra note 33, at A-9 to A-13 (§ 20-505 to 509 of the draft
legislation.
53. Id at A-1I (§ 20-507(a)(1)(i) of the draft legislation).
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* determining the adequacy of safeguards developed to
protect the rights and welfare of decisionally-incapaci-
tated subjects,54
* ensuring that legally-authorized representatives of indi-
vidual decisionally-incapacitated research participants are
provided with information which "fairly describe[s] the
risks and benefits of research participation,"55 and
* determining whether research presenting no reasonable
prospect of direct medical benefit to a group of research
subjects should be classified as "minimal risk," "a minor
increase over minimal risk," or "more than a minor in-
crease over minimal 'risk."5..'
One shortcoming of the working group's proposal is that it
doesn't address the training of IRBs or the composition of IRB mem-
bership. As discussed earlier in this article, OPRR took the IRB at the
UCLA Medical Center to task for failing to adequately monitor the
informed consent procedures and well-being of vulnerable individuals
participating in the drug washout trial.5 7 Other experts have ex-
pressed concern about the ineffectiveness of certain IRBs. 5s For ex-
ample, the notable bioethicist, Jay Katz, has expressed concerns about
the ability of local IRBs to maintain the expertise necessary to effec-
tively carry out their important functions.5 9 He has also articulated
concerns about inherent conflicts of interest, which he believes, have
the potential to hamper the ability of these Boards to objectively and
impartially protect the rights and welfare of research subjects:
The majority of IRB members are on the faculty of the insti-
tutions to which the investigators belong. They not only
share similar interests and objectives but they also know,
when sitting in judgment of a research protocol, that their
proposals may soon be subjected to similar scrutiny. Thus,
particularly in the murky area of informed consent, it is un-
likely that members of IRBs will hold investigators to a stan-
dard of disclosure and consent that would protect the
subjects of research if doing so would place impediments on
the conduct of research and, in turn, affect the well-being of
their colleagues in decisive ways.'
54. Id. at A-10 (§ 20-506(2) of the draft legislation).
55. Id. at A-II (§ 20-507(a) (2) of the draft legislation).
56. Id. (§ 20-507(b) (1) of the draft legislation).
57. See supra notes 19-20 and accompanying text.
58. See, e.g., Jay Katz, Human Experimentation and Human Rights, 38 ST. Louis U. LJ. 7,
40-41 (1993).
59. Id.
60. Id.
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We recommend that the working group consider the following
three options for enhancing the ability of IRBs to effectively carry out
their important responsibilities to protect the rights and welfare of
decisionally-incapacitated research subjects:
(1) Members of IRBs evaluating research on severe mental illnesses and
other brain disorders should receive specialized training about these disorders
and the needs of people who suffer from them. Persons with brain disorders
and family members should be integrally involved in the development, provi-
sion, and evaluation of this training.
IRBs at large, university-based research settings may be called
upon to evaluate research protocols in a number of dissimilar areas.
For example, in one sitting, an IRB may evaluate a protocol on cancer
or heart disease followed by a protocol on schizophrenia. Yet, mem-
bers of IRBs may not be sufficiently well-versed about schizophrenia
and the daily problems experienced by persons suffering from this
brain disorder to adequately evaluate potential risks and problems in-
herent in the design.
The training of IRBs on severe mental illnesses should include
more than just clinical information about these disorders. The train-
ing should also encompass information about the impact of these dis-
orders on the lives of those who suffer from them, so that IRBs are
sufficiently aware of the importance of designing studies which mini-
mize suffering and maximize supports for participants.
(2) IRBs, which regularly review human subject research on severe
mental illnesses and other brain disorders, should include consumers and fam-
ily members who have direct and personal experience with these brain disorders.
The Common Rule urges that "consideration shall be given to the
inclusion [on IRBs] of one or more individuals who are knowledgea-
ble about and experienced in working with these subjects" and who
regularly review research involving vulnerable subjects.6 We believe
that the working group's proposal should go further and require the
inclusion of individuals who have personally experienced severe
mental illnesses as consumers or family members. Without im-
pugning the motivations of individuals whose IRB membership is
based on professional expertise, the working group's proposal should
recognize that consumers and family members, by virtue of their per-
sonal experiences, are more likely to focus on those aspects of re-
search designs which may impact (positively or negatively) on the well-
being of vulnerable research subjects.
61. 45 C.F.R. § 46.107 (emphasis added)
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(3) At least one member of all IRBs evaluating and overseeing research
on severe mental illnesses or other brain disorders should be responsible for func-
tioning as a research advocate or ombudsperson on behalf of those individuals.
Investigators, as part of their informed consent responsibilities, must disclose
the role, identity and means for communicating with the research ombudsper-
son to decisionally-incapacitated individuals and their legally authorized
representatives.
Although IRBs play a crucial role in overseeing research and in
monitoring the well-being of vulnerable research subjects, members
of these boards may have little or no contact with individuals who par-
ticipate in research protocols. Moreover, research subjects, particu-
larly those who are decisionally-incapacitated, may not even know
about the existence of the IRB or the role of the IRB.6" The research
ombudsperson will be responsible for responding to concerns raised
by decisionally-incapacitated research participants or their legally au-
thorized representatives.
VI. CONCLUSION
Research represents the best hope we have for eradicating the
suffering associated with severe brain disorders such as schizophrenia,
manic-depressive illness, and others. By the same token, constraints
and limitations on the way that research is conducted means that not
all individuals will derive direct benefits from their participation in
research, and some individuals may, in fact, be harmed. The federal
regulations which govern the provision of most research on brain dis-
orders unfortunately do not set forth requirements for protecting the
rights and welfare of extremely vulnerable, decisionally-incapacitated
research subjects. The proposal developed by the Maryland Attorney
General's Research Working Group reflects the desire of its members
to develop standards which will better protect these vulnerable re-
search subjects, while not compromising the ability to conduct vitally
important research. Although the proposal may still require fine-tun-
ing or modifications, it currently represents a significant step towards
achieving this elusive balance.
62. See e.g., T.D. v. New York State Office of Mental Health, 650 N.Y.S. 2d. 173, 189-90
(N.Y. App. Div. 1996), appeal dismissed by 680 N.E.2d 617 (N.Y. 1997), leave to appeal granted
by 684 N.E.2d 281 (N.Y. 1997), and appeal dismissed by 1997 WL 785461 (N.Y. Dec. 22, 1997).
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APPENDIX
POLICIES ON STRENGTHENED STANDARDS FOR PROTECTION OF
INDIVIDUALS WITH SEVERE MENTAL ILLNESSES WHO PARTICIPATE AS
HUMAN SUBJECTS IN RESEARCH.
(Adopted by the NAMI Board of Directors, 2/4/95)
1. NAMI accepts the critical necessity for research using human
subjects, acknowledges the important contribution of persons
who become human subjects, and affirms that all such
research should be conducted in accordance with the highest
medical, ethical and scientific standards.
2. National standards to govern voluntary consent, comprehen-
sive exchange of information, and related protections of per-
sons with cognitive impairments who become research
subjects must be developed, in which the interests of persons
who become human subjects, families and other caregivers are
included.
3(A). Participants in research and their involved family members
must be fully and continuously informed, orally and in writ-
ing, about all aspects of the research throughout the process.
Research investigators must provide information in a clear,
accessible manner to ensure that participants and their
involved families fully understand the nature, risks and bene-
fits of the research.
3(B). The consent protocol must provide information, which is
clear and understandable on an individual basis for each par-
ticipant and their family members. The consent protocol must
provide information on the purposes and scale of the
research, what is hoped to be learned and prospects for suc-
cess, potential benefits and potential risks to the individual
(including options for treatment other than participation in
research, since research is not the same as treatment). The
consent protocol should also contain information concerning
the function of the Institutional Review Board (IRB), the iden-
tity of the IRB Administrator, the address and telephone
number of the IRB administrator and other information, as
appropriate.
3(). Whenever consent is given by someone other than the
research participant, the participant and involved family mem-
bers must receive information on the same basis as the person
actually giving consent.
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4. Research participants should be carefully evaluated before
and throughout the research for their capacity to compre-
hend information and their capacity to consent to continued
participation in the research. The determination of compe-
tence shall be made by someone other than the principal
investigator or others involved in the research. Except for
research protocols approved by the Institutional Review Board
(IRB) as minimal risk, whenever it is determined that the sub-
ject is not able to continue to provide consent, consent to con-
tinue participation in the research shall be sought from
families or others legally entrusted to act in the participant's
best interests.
5. Institutional Review Boards which regularly review research
proposals on severe mental illnesses must include consumers
and family members who have direct and personal experience
with severe mental illness.
6. Members of IRBs approving research on individuals with
severe mental illness must receive specialized training about
mental illness and other cognitive impairments and the needs
of individuals who experience these disorders. Persons with
severe mental illness and members of their families must be
integrally involved in the development, provision and evalua-
tion of this training.
7. Without penalty, a research participant is free to withdraw
consent at any time, with or without a stated reason. Any time
a participant terminates participation, regardless of reason,
investigators will make every effort to ensure that linkgages to
appropriate services occurs, with follow-up to assist that par-
ticipant to establish contact with appropriate service providers
and/or care-givers. If a participant disappears or terminates
their continued consent, the investigator shall contact his/her
family or others designated to receive notification and infor-
mation.
8. When participation by an individual in a research protocol is
completed, participants and/or their families are entitled to
be informed of results as soon as this information is available,
to have the opportunity to receive feedback concerning their
individual participation in the protocol, to critique the proto-
col, and to provide input concerning possible additional
research.
9. All participants in research. protocols involving the assessment
of new medications will be provided with opportunities by the
investigator for a trial on the medication being studied, so
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long as other research on the new medication has demon-
strated potential safety and efficacy.
10. All individuals who have benefited from the administration of
experimental medications in research will be provided contin-
ual access to the medication by the investigator without cost
until a source of third party payment is found.
